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In a recent Essay in Cell, McClellan and 
King argue that genomic resequencing 
rather than genome-wide association 
studies (GWAS) will be necessary to 
understand the genetic basis of common 
disease (McClellan and King, 2010). Like 
the authors, we too are excited about the 
potential for emerging sequencing tech-
nologies to facilitate discoveries that 
explain the missing heritability of com-
mon diseases. However, we disagree 
with the implication that GWAS have not 
been successful to date. Instead, we 
propose that insofar as the goal of these 
studies is to understand the etiology of 
heritable diseases, GWAS have provided 
numerous tantalizing clues for us biolo-
gists to decipher. Rather than disprove 
the common disease/common variant 
hypothesis, we find that results from 
GWAS support the contention that com-
mon polymorphisms do directly contrib-
ute to disease risk, validating the linkage 
disequilibrium-based GWAS approach 
for helping to identify variants underlying 
disease. Although we do not dismiss the 
likelihood that rare variants also contrib-
ute to common diseases, we expect that 
whole-genome sequencing approaches 
will show that the full spectrum of alleles, 
from rare to common, play important 
roles in disease etiology. Here, we argue 
that the existence of common disease-
causing polymorphisms is not inconsis-
tent with population genetic theory and 
that actual results from GWAS suggest 
that the reported associations represent 
real biology rather than false positives.
The contention that deleterious alleles 
that cause human diseases are common 
in the population may seem paradoxical, 
but several mechanisms can explain how 
such pathogenic alleles can overcome 
negative selective pressure. First, accu-
mulating evidence demonstrates that 
there is balancing selection in which a 
certain allele confers susceptibility to one 
disease while simultaneously conferring 
protection from another. The best known 
example is heterozygosity for sickle cell 
anemia, which affords protection against 
malaria. GWAS have identified other 
such instances, for example, the TCF2 
(or HNF1B) gene where alternate alleles 
are risk factors for type 2 diabetes and 
prostate cancer (Gudmundsson et al., 
2007). More generally, several loci where 
alleles have opposite effects on the risk of 
developing type 1 diabetes and Crohn’s 
disease have been reported (Wang et al., 
2010), and it is likely that more examples 
of balancing selection are yet to be dis-
covered.
The argument that common pathogenic 
variants must have withstood selective 
pressure throughout human history is 
predicated on the assumption that mod-
ern humans developed in the same envi-
ronment that we exist in today. However, 
due to the rapid acceleration of human 
development in the recent evolution-
ary timeframe, numerous environmental 
changes have occurred that may impact 
the risk of complex common diseases. 
For instance, variants that were ben-
eficial in the past may well have turned 
against their carriers as human lifestyles 
changed. The “thrifty gene hypothesis” 
suggests that variants that predispose 
to type 2 diabetes and obesity may have 
conferred a selective advantage in times 
of famine (Neel, 1962). However, in devel-
oped countries, where food tends to be 
in overabundance, type 2 diabetes and 
obesity have become common diseases. 
Furthermore, existing neutral variation 
may manifest positive or negative effects 
as new environmental modifiers come into 
play. A set of single-nucleotide polymor-
phisms (SNPs) associated with lung can-
cer and located at a locus encoding the 
nicotinic acetylcholine receptor appears 
to have a stronger effect on lung cancer 
risk in smokers born long ago relative to 
those born more recently (Landi et al., 
2009); this effect has been attributed to 
changes in the composition of cigarettes 
over time. This demonstrates that recent 
environmental changes can alter the 
disease-influencing effect of a common 
variant. These examples are likely to be 
only the tip of the iceberg of phenotypic 
effects modulated by gene-environment 
interactions.
The fact that most SNPs identified by 
GWAS do not lie in coding regions or other 
known regulatory elements is expected 
from the study design and is not evidence 
of false positives. The assumption under-
lying the design of GWAS and choice of 
genotyped SNPs is that the true functional 
allele will be nearby and correlated with 
the initial SNP through linkage disequi-
librium. When one considers linkage dis-
equilibrium, there is an observed excess of 
GWAS hits that influence promoter regions 
or change the protein-coding sequence 
of a gene and a relative paucity of hits in 
intergenic regions (Hindorff et al., 2009). 
Moreover, many disease-associated SNPs 
identified by GWAS are located in genes or 
pathways previously known or suspected 
to play a role in disease etiology. Recent 
GWAS for Alzheimer’s disease, Crohn’s 
disease, type 1 diabetes, and type 2 dia-
betes have rediscovered SNP associations 
previously reported from candidate gene 
studies. The demonstration that GWAS 
can identify common disease suscepti-
bility variants provides a positive control 
(Hindorff et al., 2009). More generally, the 
functional pathways of GWAS-identified 
genes often make sense; for instance, 
numerous inflammatory genes have been 
implicated by GWAS in inflammatory bowel 
disease (Hindorff et al., 2009). We have 
found a similar concordance between the 
literature and GWAS hits in our own work. 
In a GWAS for age-related macular degen-
eration, an SNP in complement factor H 
strongly associates with disease risk; this 
is consistent with previous suggestions 
that the complement pathway plays a role 
in disease etiology (Klein et al., 2005). Sim-
ilarly, using GWAS, we identified a germ-
line variant in the intron of the JAK2 gene 
that is associated with myeloproliferative 
neoplasms; JAK2 is known to harbor acti-
vating oncogenic somatic mutations in this 
disease (Kilpivaara et al., 2009). One would 
not expect such correlations between 
GWAS findings, genic regions, and known 
disease biology if these findings were ran-
domly distributed false positives due to 
population stratification or other causes. 
As these associations are likely to be real, 
the most logical and parsimonious expla-
nation is that, in general, GWAS success-
fully identify disease-associated variants 
and that variants found through GWAS tag 
regions important for the biology of these 
diseases.
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In light of this, it is likely that GWAS hits 
found in intergenic regions far from known 
genes are true associations whose biol-
ogy is not yet understood, rather than 
false positives. The human genome is 
incompletely annotated. Regions where 
GWAS associations have been found, but 
no known genes are located, could easily 
harbor unidentified new genes or regula-
tory elements. For instance, the authors 
point to the colon and prostate cancer risk 
SNP rs693267 located 335 kb upstream 
from the MYC gene on chromosome 8q24 
(McClellan and King, 2010). This locus has 
been shown to physically interact with 
MYC and is associated with enhanced 
Wnt signaling. Therefore, although the biol-
ogy of this locus is not fully understood, 
it suggests a paradigm where intergenic 
disease-associated SNPs alter enhancer 
elements, either directly or through linkage 
disequilibrium, and therefore cause differ-
ential regulation of disease-related genes.
This observation leads to a broader 
point: A lack of biological understanding 
of how these disease-associated vari-
ants are pathogenic does not mean that 
there is no biology to discover. Although 
our understanding of the mechanisms 
by which disease risk loci contribute to 
pathogenesis currently lags behind the 
pace at which new loci are discovered, 
promising stories continue to emerge. To 
continue the previous example, although 
no definitive correlation between the 
rs6983267 genotype and MYC expression 
has been demonstrated, MYC is known to 
be tightly regulated and the right develop-
mental time point may need to be exam-
ined to see such a correlation. Although 
further work is necessary to uncover the 
elusive mechanism by which the SNP 
confers risk, we propose that the existing 
evidence supports rather than refutes this 
SNP as a true cancer risk allele. Another 
example is a non-protein-coding region 
of chromosome 9q21 in which SNPs 
have been robustly associated with arte-
rial disease. A recent paper reported that 
targeted deletion of an orthologous region 
in mouse interferes with cis-regulation of 
nearby genes (Cdkn2a/Cdkn2b) and may 
influence vascular cell proliferation (Visel 
et al., 2010). As a third example, an intronic 
type 2 diabetes risk SNP (rs7903146) was 
recently found to overlap with a region of 
islet cell-selective chromatin, and the two 
alleles of rs7903146 correlate with the 
open/closed chromatin state of the region 
(Gaulton et al., 2010). Thus, understanding 
the mechanisms by which GWAS loci con-
tribute to disease will require considerable 
effort and time. We take this not as a sign 
that the common disease-common vari-
ant model has failed but rather that a chal-
lenge exists for the scientific community—
a challenge that must be addressed with 
both traditional experimental genetics and 
innovative new approaches.
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In a recent Essay published in Cell, 
McClellan and King discussed genetic 
heterogeneity and the potential role of 
rare genetic variants in complex human 
diseases (McClellan and King, 2010). 
These important issues, in particu-
lar the application of high-throughput 
sequencing techniques to discover 
disease genes, are highly relevant to 
genetics researchers. However, the 
authors allocated a substantial propor-
tion of their efforts to being critical of 
the utility of genome-wide association 
studies (GWAS). These particular sec-
tions of the Essay may lead to misin-
terpretation of published studies by us 
and others. For the broad readership of 
Cell and for the scientific community in 
general, we highlight our concerns in 
this Correspondence.
The authors refer to the fact that most 
single-nucleotide polymorphisms (SNPs) 
detected in GWAS reside in intergenic 
regions and consequently challenge the 
utility and reliability of GWAS with the 
question: “How did genome-wide asso-
ciation studies come to be populated by 
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